本页面由Tiger Trade Technology Pte. Ltd.提供服务

AN2 Therapeutics, Inc.

5.75
+0.12002.13%
成交量:4.42万
成交额:25.40万
市值:2.17亿
市盈率:-5.53
高:5.80
开:5.67
低:5.63
收:5.63
52周最高:7.19
52周最低:1.00
股本:3,773.62万
流通股本:1,974.83万
量比:1.51
换手率:0.22%
股息:- -
股息率:- -
每股收益(TTM):-1.0401
每股收益(LYR):-1.1641
净资产收益率:-50.12%
总资产收益率:-30.80%
市净率:2.86
市盈率(LYR):-4.94

数据加载中...

公司资料

公司名字:
AN2 Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2017
员工人数:
- -
公司地址:
1300 El Camino Real,Suite 100,Menlo Park,California,United States
邮编:
94025
电话:
传真:
- -
简介:
AN2 Therapeutics, Inc.于2017年2月24日在特拉华州注册成立,并于2019年11月开始运营。该公司是一家临床阶段的生物制药公司,专注于利用其硼化学平台发现和开发新型小分子疗法。其研发管线针对血液疾病、感染性疾病和肿瘤学领域。

董事

名称
职位
Eric Easom
President, Chief Executive Officer, Chair and Director
Gilbert Lynn Marks
Independent Director
Joseph Zakrzewski
Independent Director
Kabeer Aziz
Independent Director
Margaret FitzPatrick
Independent Director
Melvin Spigelman
Independent Director
Patricia Martin
Independent Director
Rob Readnour
Independent Director
Stephanie Wong
Independent Director

股东

名称
职位
Eric Easom
President, Chief Executive Officer, Chair and Director
Joshua Eizen
Chief Legal Officer and Chief Operating Officer
Lucy Day
Chief Financial Officer
Sanjay Chanda
Chief Development Officer
Sarah Williams
Vice President, Controller and Principal Accounting Officer
Stephen Prior
Chief Strategy Officer